Life Sciences/Healthcare

Life Sciences/Healthcare

The Life Sciences/Healthcare sector is one of the most densely regulated markets. Market participants face a variety of challenges that require an interdisciplinary approach to legal advice.

We advise and represent leading international pharmaceutical manufacturers, medical device manufacturers, biotech companies, hospitals, nursing homes, health insurance companies and service providers. Our interdisciplinary team supports clients in their day-to-day business, with M&A transactions and venture capital investments, regulatory issues, competition and therapeutic product advertising and the protection of industrial property rights. In addition, we advise on all labor law issues relating to corporate restructuring and the optimization of work processes, tax structuring, compliance issues, digitalization issues, national and EU-wide proceedings against regulatory measures, product safety issues, product liability cases and other disputes, including litigation before national and EU courts.

Together with our clients, we develop new solutions and business models, such as digitalization of medical products, cultivation of medical cannabis in Germany or cooperations with start-ups. By using Legal Tech, we help to control and optimize internal processes.

Examples of our advisory services:

  • Representation of a German pharmaceutical company in a lawsuit before the European Courts (EGC and ECJ) against the EU Commission in the context of the successful challenge of a regulatory measure concerning a drug containing estradiol
  • Structuring of clinical studies under the aspect of data protection law, especially in cross-border situations
  • Negotiation of cross-border supply agreements including regulatory issues relating to the import and export of medical cannabis
  • Reorganization of the field sales force of a pharmaceutical company, in particular advice on the employer's structuring rights in case of changes in the distribution territories and reporting channels as well as on questions regarding the co-determination rights of works councils under industrial constitution law
  • Cooperation between international pharmaceutical companies in the production of vaccines against coronavirus
  • Solution of regulatory and public law issues in connection with the use of mobile corona test stations at European airports
  • Market entry of CBD products in the lifestyle segment, including distribution possibilities in consideration of the regulatory restrictions
  • Venture capital investment in a medical device manufacturer, including verification of the business model
  • Advice to one of the largest healthcare associations, in connection with, inter alia, digitalization issues
  • Advice to pharmacies in the acquisition of service providers and a medication tracker app
Franziska Katterbach

Franziska Katterbach

PartnerRechtsanwältin

OpernTurm
Bockenheimer Landstraße 2-4
60306 Frankfurt am Main
T +49 69 707968 217
M +49 160 2991006

Email

LinkedIn

Further contacts

Newsbeiträge

Related news

Life Sciences/Healthcare05.02.2025 Newsletter

Germany’s Cannabis Market: Regulatory Growth and International Expansion Opportunities

In two articles we analyse the developments and opportunities in the German cannabis market: Franziska Katterbach examines regulatory changes in the medical sector, while Jonathan Sherman highlights how German companies can leverage Canadian capital markets for their expansion.

Read more

Oppenhoff advises Lange Medtech on the acquisition of the German medical technology company ErgoSurg

Oppenhoff has comprehensively advised the Chinese Lange Medtech Group on the acquisition of a majority stake in ErgoSurg GmbH. The previous managing shareholder of ErgoSurg will invested.

Read more

Oppenhoff advises Bayer on acquisition of HiDoc Technologies

Oppenhoff has advised Bayer AG on the acquisition of HiDoc Technologies GmbH. With the strategic acquisition of HiDoc Technologies planned for Q1 2025, Bayer is expanding its portfolio in the field of digital health and further expanding its involvement in the area of self-medication.

Read more

NL-Anmeldung